Enhancing ulcerative colitis treatment with traditional Chinese medicine

Inflammatory bowel disease,particularly ulcerative colitis(UC),poses significant treatment challenges due to its chronic nature and potential for severe complications.This editorial reviews a recent network meta-analysis that evaluated the efficacy of and highlighted the superior outcomes achieved by combining each of five traditional Chinese medicine(TCM)formulations with mesalazine for the adjuvant treatment of UC.Clinical outcomes included enhanced mucosal healing,improved quality of life,and reduced recurrence rates.Additionally,the combination therapy resulted in a lower incidence of adverse reactions compared with mesalazine monotherapy.Despite these promising results,limitations such as variability in study quality and TCM dosage highlight the need for further highquality,large-sample,multicenter randomized controlled trials.This editorial underscores the potential of TCM in enhancing UC management and calls for more rigorous research to substantiate these findings and refine clinical guidelines.

CLINICAL STUDY ON 118 CASES OF ULCERATIVE COLITIS TREATED BY INTEGRATION OF TRADITIONAL CHINESE AND WESTERN MEDICINE

118 cases of ulcerative colitis were treated by integration of traditional Chinese and Western medicine. Another 86 cases of ulcerative colitis were treated by simple western drugs as controls. The therapeutic effects for both groups were observed and compared after two therapeutic courses of 40 consecutive days. As a result, 39 cases were cured, 60 cases improved and 19 cases failed, with a total effective rate of 84% in the treatment group; in the control group, 15 cases were cured, 37 cases improved and 34 cases failed, with a total effective rate of 60.5%. Statistically, the difference was very significant (P

Acute moderate to severe ulcerative colitis treated by traditional Chinese medicine:A case report

BACKGROUND Ulcerative colitis(UC),also known as chronic nonspecific UC,is an inflammatory bowel disease characterized by diffuse colonic mucosal inflammation.The incidence and prevalence of UC have risen markedly,and the disease seriously affects the quality of life of patients and imposes a great burden on the world health care infrastructure and economy.CASE SUMMARY Case I describes a 34-year-old female who came to see a doctor because of repeated abdominal pain,diarrhoea and purulent blood for 2 mo.This patient had UC with an initial onset,an active stage and a wide range of lesions.After the poor effect of sulfasalazine and mesalazine,the patient’s condition gradually deteriorated,her abdominal pain and bloody stools continued,and anemia occurred.She began treatment with the Chinese medicine Guizhi Dahuang decoction,which was taken orally twice a day,200 mL each time.After 6 mo of treatment,abdominal pain,diarrhoea,bloody stool and other symptoms disappeared.No abnormality was found by repeat electronic enteroscopye,and the anemia was corrected.The patient’s condition did not recur after nearly 4 years of follow-up.CONCLUSION A series of symptoms in this UC patient significantly improved with the administration of traditional Chinese medicine.

Analysis on the therapeutic effects of integrated traditional Chinese and Western medicine on ulcerative colitis and its effects on coagulation function and inflammatory factors

Objective:To analyze the therapeutic effects of Integrated Traditional Chinese and Western Medicine on ulcerative colitis (UC) and its effects on coagulation function and inflammatory factors.Methods: 220 cases of patients with UC were selected as the research subjects and randomly divided into the observation group and the control group, 110 cases were included into each group. The patients in the control group were treated with single western medicine, while the patients in the observation group were treated with enema treatment of traditional Chinese Medicine. The clinical therapeutic effects of the two groups were evaluated and compared. The blood coagulation indexes of the activated partial thromboplastin time (APTT), prothrombin time (PT), the plasma fibrinogen (Fib), the D dimer (D-D) of two groups patients who in the treatment were detected and compared. The serum tumor necrosis factor (TNF-α), interleukin-6 (IL-6), interleukin-8 (IL-8) levels of the patients in the two groups were measured and compared.Results: The clinical efficiencies of the observation group and the control group were 97% and 75%, the clinical efficiencies and the therapeutic effects of the observation group were better than those in the control group, there were statistically significant differences between the two groups. The plasma Fib levels and the plasma D-D levels after the treatment of the patients in the two groups were significantly lower than those before the treatment, the difference was statistically significant. The plasma Fib levels and the plasma D-D levels after the treatment of the patients in the observation group were lower than those in the control group, the difference was statistically significant. The serum inflammatory factors levels after the treatment of the patients in the two groups were significantly lower than those before the treatment, the difference was statistically significant. The serum inflammatory factors levels after the treatment of the patients in the observation group were lower than those in the control group, the difference is powerful and have statistically significant.Conclusion: The application of Integrated Traditional Chinese and Western Medicine in the treatment of UC can improve the therapeutic effect significantly, correct imbalance of the patients' coagulation dissolution function, reduce the degree of inflammatory reaction, which benefits to promote of the patients' rehabilitation, reduce the incidence of complications and improve the prognosis of patients.

Chinese research into severe ulcerative colitis has increased in quantity and complexity

AIM To investigate the current state of research output from Chinese studies into severe ulcerative colitis(SUC) using a bibliometric analysis of publications. METHODS The contents of the Chinese periodical databases WANFANG, VIP, and China National Knowledge Infrastructure were searched for all papers regarding UC or SUC published in last the 15 years (from 2001 to 2015). The number of publications in each year was recorded to assess the temporal trends of research output. All SUC related publications were downloaded and the complexity of this research was evaluated with methods described previously. The number of patients with SUC reported each year was recorded and their clinical characteristics were analyzed using information available in the relevant papers. RESULTS There were 13499 publications regarding UC published in Chinese medical journals between 2001 and 2015, of which 201 focused on SUC. The number of publications increased rapidly with more than half of all papers being published in the most recent 5-year period. There was a significant increase in analyticalstudies and clinical trials over the study period (P < 0.01), with research into the management of SUC, included pharmacotherapy, nutrition support as well as surgery, predominating. Almost half (46.2%) of the observational analytical studies and clinical trials focused on Traditional Chinese Medicine, with little research on the efficacy of cyclosporin and infliximab in disease management. About 6222 patients with SUC were reported in the 201 SUC relevant papers, with a ratio of male/female of 1.38. The number of patients reported in each 5-year period significantly increased. The colectomy rate and short-term mortality rate were 7.7% and 0.8% respectively. The most commonly employed operation was total proctocolectomy with ileal pouch-anal anastomosis.CONCLUSION The output and complexity of research related to SUC in China increased significantly over the previous 15 years, however few of these studies focused on salvage therapy.

Glucose intolerance and diabetes mellitus in ulcerative colitis: Pathogenetic and therapeutic implications

Diabetes mellitus is one of the most frequent co-morbidities of ulcerative colitis patients.The epidemiological association of these diseases suggested a genetic sharing and has challenged gene identification.Diabetes co-morbidity in ulcerative colitis has also relevant clinical and therapeutic implications,with potential clinical impact on the follow up and outcome of patients.These diseases share specific complications,such as neuropathy,hepatic steatosis,osteoporosis and venous thrombosis.It is still unknown whether the coexistence of these diseases may increase their occurrence.Diabetes and hyperglycaemia represent relevant risk factors for postoperative complications and pouch failure in ulcerative colitis.Medical treatment of ulcerative colitis in patients with diabetes mellitus may be particularly challenging.Corticosteroids are the treatment of choice of active ulcerative colitis.Their use may be associated with the onset of glucose intolerance and diabetes,with difficult control of glucose levels andwith complications in diabetic patients.Epidemiologic and genetic evidences about diabetes co-morbidity in ulcerative colitis patients and shared complications and treatment of patients with these diseases have been discussed in the present review.

Protective Effect of Jiechangning (结肠宁) Decoction in Treating Experimental Ulcerative Colitis in Guinea Pigs

Objective: To study the therapeutic effects and mechanism of Jiechangning (结肠宁, JCN) decoction on carrageenan induced experimental ulcerative colitis (UC). Methods: After sensitizing guinea pigs with carrageenan, we established UC animal models by free drinking water containing 2% acid degraded carrageenan (ADC). JCN decoction was orally administered once a day for 2 weeks after carrageenan treatment. Salicylazosulfapyridine (SASP) and normal saline were given to the other two groups as control. The levels of colon lipid peroxide (LPO), acid phosphatase (ACP)activity and tumor necrosis factor-α (TNF-α) were measured; colitis activity score (CAS) was carried out for assessment of the degree of tissue inflammation and injury; the colonic pathological changes were examined simultaneously with hematoxylin and eosin (HE) and toluidine blue staining used to evaluate the therapeutic effects of JCN decoction and SASP. Results: Experimental colitis models resembling human UC were successfully induced. The levels of tissue LPO, ACP activity and the content of tissue TNF-α were markedly increased in the model group as compared with the normal control group ( P <0.01) and were positively correlated with CAS. JCN decoction could reverse these changes like SASP. HE staining showed that JCN decoction and SASP could reduce CAS and the degree of tissue injury, toluidine blue staining revealed that mucosa and submucosa red metachromasia pellets in JCN group and SASP group were markedly fewer than those in the model group. Conclusion: JCN decoction is effective in treating experimental UC, which provides theoretical basis for its clinical application.

Treatment of inflammatory bowel disease:A review of medical therapy

Crohn’s disease (CD) and ulcerative colitis (UC) are chronic inflammatory diseases of the gastrointestinal tract. While a cure remains elusive, both can be treated with medications that induce and maintain remission. With the recent advent of therapies that inhibit tumor necrosis factor (TNF) alpha the overlap in medical therapies for UC and CD has become greater. Although 5-ASA agents have been a mainstay in the treatment of both CD and UC, the data for their efficacy in patients with CD, particularly as maintenance therapy, are equivocal. Antibiotics may have a limited role in the treatment of colonic CD. Steroids continue to be the first choice to treat active disease not responsive to other more conservative therapy; non- systemic steroids such as oral and rectal budesonide for ileal and right-sided CD and distal UC respectively are also effective in mild-moderate disease. 6-mercaptopurine (6-MP) and its prodrug azathioprine are steroid-sparing immunomodulators effective in the maintenance of remission of both CD and UC, while methotrexate may be used in both induction and maintenance of CD. Infliximab and adalimumab are anti-TNF agents approved in the US and Europe for the treatment of Crohn's disease, and infliximab is also approved for the treatment of UC.

A Multi-center,Randomized, Single-blind,Controlled Clinical Study on the Efficacy of Composite Sophora Colon-Soluble Capsules in Treating Ulcerative Colitis

Objective： To evaluate the safety and efficacy of composite sophora colon-soluble capsule （CSCC） in treating ulcerative colitis （UC） of the damp-heat accumulation syndrome pattern （DHAS） and to prepare a basis for a phase Ⅲ clinical trial.Methods： A multi-center,randomized,single-blind,and positive drug parallel-controlled design was adopted.There were 126 patients of UC-DHAS stratified and assigned equally to three groups.Patients in two CSCC treated groups,Groups T1 and T2,were treated orally with high （six capsules,thrice a day） and low （four capsules,thrice a day） doses CSCC,and patients in the control group were treated orally with Mesalazine Enteric-coated Tablets （four tablets,thrice a day）,respectively,all for eight weeks.The clinical efficacy and safety of treatments were evaluated through clinical symptom observations and colonoscopic examinations.Results： （1） Full analysis set （FAS） and per-protocol set （PPS） analyses showed the comprehensive curative effect in Groups T1,T2,and the control group,obtaining the values of 85.7%,92.9%,and 71.4% （P=0.330）,and 89.5%,92.7%,and 73.2% （P=0.552）,respectively,demonstrating no statistical significance among the three groups.（2） FAS and PPS analysis showed the efficacy on membranous lesions in Groups T1,T2,and the control group,obtaining the values of 83.3%,92.9%,and 73.8% （P=0.063）,and 86.8%,92.7%,and 75.6% （P=0.070）,respectively,showing statistical insignificance among the three groups.（3） FAS analysis showed an efficacy tendency on improving tenesmus （P=0.056）.No changes were found in improving the other symptoms,and statistical significance was not shown among the three groups （P〉0.05）.PPS analysis showed the efficacy on single item symptom in Groups T1,T2,and the control group was not statistically significant among the three groups （P=0.082）.Conclusions： The comprehensive effect of CSCC in treating UC is basically equivalent to that of Mesalazine enteric-coated tablet;however,the tendency was shown to improve symptoms.Its efficacy could not be raised by increasing the dosage used.Therefore,the recommended dosage of CSCC is four capsules,three times a day.

Effects of Modified Sanhuang Decoction (加味三黄汤) Enemaon Serum Tumor Necrosis Factor-α and Colonic Mucosa Interleukin-1β,Interleukin-6 Levels in Ulcerative Colitis Rats

Objective：To investigate the effects of Modified Sanhuang Decoction（加味三黄汤,MSD）enema on the serum tumor necrosis factor alpha（TNF-α）and colonic mucosa interleukin-1β（IL-1β）,interleukin-6（IL-6）levels in experimental ulcerative colitis（UC）rats.Methods：Forty-five male Wistar rats were randomly divided into 4 groups：normal group（n=12）,model group（n=11）,salazosulfapyridine（SASP）group（n=11）and MSD group（n=11）.The UC model was induced by 2,4,6-trinitrobenzene sulfonic acid（TNBS）/ethanol solution.Rats in the normal group and model group were clystered with 0.9%normal saline,while in the SASP group and MSD group were clystered with SASP and MSD enema,respectively.After drug administration（10 mL/kg body weight,for 7 days）,colonic gross changes and colonic mucosa histology were observed,serum TNF-αand colonic mucosa IL-1β,IL-6 levels were tested by enzyme linked immunosorbent assay and radioimmunoassay,respectively.Results：As compared with the normal group,the experimental UC rats,the colonic mucosal damage index scores（CMDIs）,histopathological scores（HS）and the serum TNF-a and colonic mucosa IL-1β,IL-6 levels significantly increased（P〈0.05 or P〈0.01）.In the MSD and SASP groups,the ulcer area significantly reduced,and edema disappeared.The CMDIs,HS,the serum TNF-a and colonic mucosa IL-1β,IL-6 levels in the MSD and SASP groups significantly decreased（P〈0.05 or P〈0.01）compared with the model group.The CMDIs in the MSD group were lower than that in the SASP group（P〈0.05）,but there were no significant differences in HS,serum TNF-αor colonic mucosa IL-1β,IL-6 levels between the MSD and SASP groups.Conclusion：MSD enema can improve colonic mucosa impairment and decrease serum TNF-αand colonic mucosa IL-1β,IL-6 levels in experimental UC.

七味白术理肠方联合脐灸治疗激素依赖溃疡性结肠炎的临床疗效及对激素撤退的影响

目的观察七味白术理肠方联合脐灸治疗激素依赖溃疡性结肠炎(UC)的临床疗效及对激素撤退的影响。方法将90例激素依赖UC患者按照随机数字表法分为2组,对照组45例予口服美沙拉嗪肠溶片治疗,治疗组45例予七味白术理肠方口服联合脐灸治疗。治疗3个月后,比较2组治疗前后中医证候评分、Baron内镜评分、T淋巴细胞亚群(CD3^(+)、CD4^(+)、CD8^(+)、CD4^(+)/CD8^(+))水平变化,统计2组疗效及激素撤退率。结果治疗组总有效率88.89%(40/45),对照组总有效率62.22%(28/45),治疗组临床疗效优于对照组(P<0.05)。2组治疗后中医证候各项评分均较本组治疗前降低(P<0.05),且治疗组治疗后均低于对照组(P<0.05)。2组治疗后Baron内镜评分均较本组治疗前降低(P<0.05),且治疗组治疗后低于对照组(P<0.05)。2组治疗后CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)均较本组治疗前升高(P<0.05),且治疗组治疗后均高于对照组(P<0.05),2组治疗后CD8^(+)均降低(P<0.05),且治疗组治疗后低于对照组(P<0.05)。治疗组激素撤退率高于对照组(P<0.05)。结论七味白术理肠方联合脐灸能有效改善激素依赖UC患者的中医证候疗效,促进肠黏膜损伤愈合及激素撤退,提高患者的免疫功能,具有良好的临床疗效。

中药脐疗治疗溃疡性结肠炎缓解期疗效观察

目的观察中药脐疗干预治疗溃疡性结肠炎缓解期临床效果。方法选取2021年1月至2023年3月在潍坊医学院附属高密市人民医院消化内科就诊溃疡性结肠炎缓解期患者,按照随机数表法分为治疗组、对照组,每组各35例。对照组口服美沙拉嗪肠溶片1.0 g,tid;治疗组同时给予中药脐疗“十味抗炎方”凝胶剂。采用改良Mayo评分评价溃疡性结肠炎严重程度;溃疡性结肠炎疾病活动指数评价疾病活动度;炎症性肠病生存量表评价生存质量;检查炎症因子白细胞介素-6、白细胞介素-8和肿瘤坏死因子-α;选择抑郁自评量表和焦虑自评量表评价患者心理情况。结果治疗组第5、6个月Mayo评分和疾病活动指数得分低于对照组,差异有统计学意义(P<0.05);治疗组第3、4、5、6个月炎症性肠病生存量表得分高于对照组,差异有统计学意义(P<0.05);治疗组第3、6个月炎症因子低于对照组,差异有统计学意义(P<0.05);治疗组第3、6个月抑郁和焦虑自评量表评分低于对照组,差异有统计学意义(P<0.05)。结论中药脐疗提升患者生活质量,改善预后,临床疗效优于对照组。

艾灸联合虎地肠溶胶囊治疗活动期溃疡性结肠炎临床观察

目的探究艾灸联合虎地肠溶胶囊治疗活动期溃疡性结肠炎的临床效果。方法采用随机数字表法将南昌大学第四附属医院2019年7月—2021年8月收治的60例活动期溃疡性结肠炎患者分为两组,各30例。对照组应用美沙拉嗪肠溶片治疗,试验组在此基础上应用艾灸联合虎地肠溶胶囊治疗。对比两组临床疗效、肠黏膜病变评分、Mayo活动指数评分及不良反应发生情况。结果试验组的治疗总有效率为93.33%(28/30),高于对照组的73.33%(22/30)(P<0.05)。治疗后,试验组肠黏膜病变评分、Mayo活动指数评分均低于对照组(P<0.05)。试验组不良反应发生率为3.33%(1/30),对照组为13.33%(4/30),差异无统计学意义(P>0.05)。结论艾灸联合虎地肠溶胶囊能够有效减轻活动期溃疡性结肠炎患者肠黏膜病变程度,改善各临床症状,疗效显著,且安全可靠,值得推广应用。

针刺结合中药保留灌肠对溃疡性结肠炎的疗效及免疫功能的影响

目的:探讨针刺结合中药保留灌肠治疗溃疡性结肠炎(UC)的临床疗效及其改善免疫功能的作用。方法:选取符合纳入标准的UC患者70例,依据随机数字表随机分为观察组和对照组,各35例。对照组给予美沙拉嗪缓释片,观察组在对照组基础上加用针刺与中药保留灌肠疗法,两组均治疗8周。比较两组患者治疗前后血清免疫功能指标CD3^(+)、CD4^(+)与CD8^(+)含量、炎症因子指标白细胞介素(IL)-1β、IL-23与转化生长因子-β1(TGF-β1)的改善情况。结果:治疗后,两组患者TGF-β1、CD3^(+)、CD4^(+)含量均较治疗前明显升高(P<0.05),IL-1β、IL-23、CD8^(+)含量下降(P<0.05);且观察组治疗后TGF-β1、CD3^(+)和CD4^(+)水平均高于对照组(P<0.05),IL-1β、IL-23、CD8^(+)水平均低于对照组(P<0.05)。结论:针刺结合中药保留灌肠治疗能显著改善UC患者免疫功能,降低其炎症因子水平。

针刺联合火龙罐治疗轻中度溃疡性结肠炎的疗效观察

目的观察针刺联合火龙罐治疗轻中度溃疡性结肠炎的临床疗效及对患者血清炎症因子、肠黏膜屏障功能和大便肠道菌群的影响。方法将120例轻中度溃疡性结肠炎患者随机分为观察组和对照组,每组60例。对照组予口服美沙拉嗪片治疗,观察组在对照组治疗基础上予针刺联合火龙罐治疗。观察两组治疗前后溃疡性结肠炎改良梅奥(Mayo)评分、炎症性肠病生存质量问卷(inflammatory bowel disease questionnaire,IBDQ)评分和肠镜Baron量表评分的变化,观察两组治疗前后患者血清炎症因子指标[肿瘤坏死因子-α(tumor necrosis factor-α,TNF-α)、白介素-6(interleukin-6,IL-6)和C-反应蛋白(C-reactive protein,CRP)]以及肠黏膜屏障功能指标[低氧诱导因子-1α(hypoxia inducible factor-1α,HIF-1α)、二胺氧化酶(diamine oxidase,DAO)和内毒素(endotoxin,ET)]水平的变化,观察两组治疗前后患者大便中肠道菌群(肠球菌、大肠杆菌、乳酸杆菌和双歧杆菌)活菌对数值的变化。比较两组临床疗效。结果观察组总有效率为96.6%,高于对照组的85.7%(P<0.05)。治疗后,两组Mayo和Baron评分均降低(P<0.05),IBDQ评分均升高(P<0.05);且观察组上述评分均优于对照组(P<0.05)。治疗后,两组血清TNF-α、IL-6、CRP、ET、HIF-1α和DAO水平均降低(P<0.05),且观察组均低于对照组(P<0.05)。治疗后,两组肠球菌和大肠杆菌水平均降低(P<0.05),乳酸杆菌和双歧杆菌水平均升高(P<0.05);且观察组上述菌群水平均优于对照组(P<0.05)。结论在口服美沙拉嗪片治疗基础上,针刺联合火龙罐可明显缓解轻中度溃疡性结肠炎患者的临床症状,改善血清炎症因子水平,提高肠黏膜屏障功能,调节大便肠道菌群。

藿香正气散配合脐疗治疗大肠湿热型溃疡性结肠炎临床观察

目的分析加味藿香正气散配合脐疗治疗大肠湿热型溃疡性结肠炎的临床效果。方法采用随机数字表法将莲花县人民医院于2019年1月—2021年12月收治的80例大肠湿热型溃疡性结肠炎患者分为参照组与观察组,各40例。参照组行常规西医治疗,观察组在参照组基础上行加味藿香正气散配合脐疗,对比两组炎性因子水平、中医证候积分、临床疗效、不良反应总发生率。结果治疗后,观察组腹痛、腹泻、脓血便、里急后重的中医证候积分均较参照组更低,差异均有统计学意义(P<0.05);观察组白细胞介素-6(IL-6)、超敏C反应蛋白(hs-CRP)、肿瘤坏死因子-α(TNF-α)水平较参照组更低,差异均有统计学意义(P<0.05);两组头晕、皮疹、肝功能异常等不良反应总发生率比较,差异无统计学意义(P>0.05);观察组治疗总有效率为92.50%(37/40),高于参照组的75.00%(30/40)(P<0.05)。结论给予大肠湿热型溃疡性结肠炎患者加味藿香正气散配合脐疗,不仅有助于缓解临床症状,还能够改善机体炎症反应,效果显著且安全可靠,值得临床推广应用。

化湿运脾汤联合美沙拉秦治疗脾虚湿蕴型溃疡性结肠炎临床观察

目的:观察化湿运脾汤联合美沙拉秦治疗脾虚湿蕴型溃疡性结肠炎的临床疗效。方法:选取70例脾虚湿蕴型溃疡性结肠炎患者,采用随机字母表法将其分为两组各35例。对照组予美沙拉秦肠溶片口服,治疗组在对照组基础上予化湿运脾汤治疗,疗程为2个月。对两组治疗前后的中医证候评分(腹痛、腹泻、里急后重、便血)、C-反应蛋白水平及中医临床疗效变化进行比较。结果:治疗组的显效率96.87%明显高于对照组的84.84%(P<0.05)。两组临床症状积分(腹痛、腹泻、里急后重、便血)及C-反应蛋白水平均下降(P<0.05),且治疗组优于对照组(P<0.05)。结论:化湿运脾汤联合美沙拉秦治疗脾虚湿蕴型溃疡性结肠炎疗效良好,对腹痛、腹泻、里急后重、便血的症状有明显的缓解作用,能有效降低炎性指标C-反应蛋白水平。

徐长卿为君药的中药方治疗活动期溃疡性结肠炎临床观察

目的观察徐长卿为君药的中药方治疗活动期轻中度溃疡性结肠炎(UC)的临床疗效。方法将60例患者随机分为试验组和对照组,各30例。试验组给予徐长卿为君药的中药方口服,对照组给予美沙拉嗪肠溶片,比较两组治疗前后腹泻、脓血便、腹痛、腹胀、肛门灼热、里急后重、总体症状积分及红细胞沉降率、C反应蛋白水平,并监测不良反应。结果治疗后,两组患者的腹泻、脓血便、腹痛、腹胀、肛门灼热、里急后重、总体症状积分及红细胞沉降率、C反应蛋白水平均有明显改善(P<0.05),并且试验组患者脓血便及总体症状的改善优于对照组患者(P<0.05)。仅对照组有1例患者丙氨酸氨基转移酶(ALT)升高。结论徐长卿为君药的中药方治疗活动期轻中度UC是有效且安全的,并且对脓血便及总体症状的改善优于美沙拉嗪肠溶片。

基于R语言探析巩跃生治疗溃疡性结肠炎的用药规律

目的:总结巩跃生治疗溃疡性结肠炎的遣方用药规律。方法:收集2021年1月1日至2022年12月31日巩跃生教授治疗溃疡性结肠炎的医案574则,提取首诊处方建立处方数据库,R软件中运用频数统计分析、关联规则分析、聚类分析等方法分析用药规律。结果:研究共纳入有效处方384份,涉及中药135味,药性以寒、温为主,药味以苦、甘、辛为主,归经多为脾经、胃经、肝经。中药关联规则分析得到强关联规则49条,其中置信度最高的药对为“连翘-栀子”,三药组合为“党参,山药-白术”;与大肠湿热证相关的核心药物有黄柏、白头翁、黄连、牡丹皮、乌梅等;层次聚类将30味高频中药聚为3类。结论:巩跃生治疗溃疡性结肠炎注重五脏论治,以脾胃为主,运用清热利湿、温补脾胃、调和气血等治法,体现了理法同达、药证合一、顾病求本的学术思想。

孙光荣止痢汤治疗溃疡性结肠炎临床观察

目的探究孙光荣止痢汤治疗溃疡性结肠炎的疗效。方法按照随机数字表法将2022年1月—2023年6月收治的120例溃疡性结肠炎患者分为试验组和对照组,各60例。对照组予以常规西药治疗,试验组在对照组基础上加用孙光荣止痢汤,2组均连续治疗4周。比较2组临床疗效、中医证候积分、炎性因子水平、Sutherland评分。结果治疗后,试验组总有效率高于对照组(P<0.05),2组中医证候积分、IL-6、TNF-α、CRP、WBC、Sutherland评分均降低(P<0.05),试验组均低于对照组(P<0.05)。结论孙光荣止痢汤治疗溃疡性结肠炎可提高临床疗效,改善临床症状,降低炎性反应,值得推广。